Sector
PharmaceuticalsOpen
₹171.5Prev. Close
₹171.35Turnover(Lac.)
₹34.46Day's High
₹176Day's Low
₹162.852 Week's High
₹307.252 Week's Low
₹75.12Book Value
₹67.34Face Value
₹10Mkt Cap (₹ Cr.)
104.01P/E
13.7EPS
12.51Divi. Yield
017 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
25 May 2024
12:00 AM
AGM
Announcement Date: 25 May, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 35.73 | 27.97 | 25.29 | 22.35 |
Net Worth | 41.96 | 34.2 | 31.52 | 28.58 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 50.86 | 54.25 | 43.79 | 40.79 |
yoy growth (%) | -6.24 | 23.88 | 7.34 | 14.99 |
Raw materials | -32.78 | -28.54 | -24.48 | -24.71 |
As % of sales | 64.44 | 52.62 | 55.9 | 60.59 |
Employee costs | -6.23 | -6.03 | -5.27 | -3.69 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3.87 | 10.5 | 5.64 | 4.72 |
Depreciation | -1.01 | -1.03 | -1.02 | -0.93 |
Tax paid | -1.02 | -3.32 | -1.58 | -1.19 |
Working capital | 9.94 | 7.87 | 2.34 | 1.93 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.24 | 23.88 | 7.34 | 14.99 |
Op profit growth | -58.85 | 82.52 | -1.18 | 44.09 |
EBIT growth | -57.12 | 79.49 | 5.02 | 45.54 |
Net profit growth | -60.37 | 77.07 | 14.87 | 332.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sharat Deorah
Whole-time Director
Siddhartha Deorah
Independent Director
Kavita Vijayakant Sharma
Whole-time Director
Kiran Kulkarni
Company Sec. & Compli. Officer
Sweta Agarwal
Independent Director
Vishal Kailash Chandra Jhunjhunwala
Independent Director
Mahendra Kumar Daga
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Auro Laboratories Ltd
Summary
Auro Laboratories Ltd, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes. The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra. The facility has all the required certifications from Indian authorities and European registration organizationSince inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards. Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA.The Companys primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments. Currently, it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally, it also undertake Toll/Custom Manufacturing for APIs and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum.Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia, Middle East and several European Countries. Some of the countries the company exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spa
Read More
What is the Auro Laboratories Ltd share price today?
The Auro Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹166.95 today.
What is the Market Cap of Auro Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Auro Laboratories Ltd is ₹104.01 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Auro Laboratories Ltd?
The PE and PB ratios of Auro Laboratories Ltd is 13.7 and 2.54 as of 22 Jul ‘24
What is the 52 Week High and Low of Auro Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Auro Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Auro Laboratories Ltd is ₹75.12 and ₹307.2 as of 22 Jul ‘24
What is the CAGR of Auro Laboratories Ltd?
Auro Laboratories Ltd's CAGR for 5 Years at 24.84%, 3 Years at -0.45%, 1 Year at 113.76%, 6 Month at 35.99%, 3 Month at -8.22% and 1 Month at -15.13%.
What is the shareholding pattern of Auro Laboratories Ltd?
The shareholding pattern of Auro Laboratories Ltd is as follows:
Promoters - 52.15 %
Institutions - 0.01 %
Public - 47.84 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
